Pliant Therapeutics Inc (PLRX)

$1.31 -0.23 (-14.94%)
Market Cap 91.56M
Revenue (ttm) 0.00
Net Income (ttm) -210.30M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.15
Volume 15,678,200
Avg Vol 1,129,030
Day's Range N/A - N/A
Shares Out 61.45M
Stochastic %K 31%
Beta 1.29
Analysts Sell
Price Target $2.78

Company Profile

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonal...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6770
Address:
331 Oyster Point Boulevard, South San Francisco, United States
elmono
elmono Dec. 5 at 8:17 AM
$PLRX when does this bio zombie receive a 3 usd cash offering from Tang to take it out of its misery? Over 4 USD in cash per share so shouldn’t take long
0 · Reply
Iightning
Iightning Dec. 5 at 6:47 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PLRX Contract: Dec 19 $1C Entry: 0.30 Exit: 0.55 Return: +83.89% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 5 at 12:36 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PLRX Contract: Dec 19 $1C Entry: 0.30 Exit: 0.55 Return: +83.89% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 4 at 9:59 PM
$GRI no matter the bear thesis IM STILL GAMBLING ON iPf DATA. I know what the market prices it at. Look at $PLRX $TVRD $ARCT
2 · Reply
anarquia99
anarquia99 Dec. 4 at 8:58 PM
$PLRX nice rebound I out here
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 4 at 8:21 PM
$GRI iPf Data worth at Least 300 million market cap Ask $PLRX lost 900 million market cap $TVRD lost over 300 million market cap $ARCT with a 6 person trial Lost 300 million market cap $GRI bio market cap 6.4 million market U do the math on a 300 million market cap boost
1 · Reply
aw20
aw20 Dec. 4 at 8:15 PM
$PLRX and loaded more at 1.17 👀
0 · Reply
Bellbent
Bellbent Dec. 4 at 8:02 PM
$PLRX they want this under a dollar
0 · Reply
cristiraj
cristiraj Dec. 4 at 8:01 PM
$PLRX merck want to buy them very cheap
0 · Reply
sandman7473
sandman7473 Dec. 4 at 7:59 PM
$PLRX loading walls are up. think there are dumping to load. Data was good.
0 · Reply
Latest News on PLRX
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Dec 4, 2025, 1:53 PM EST - 14 hours ago

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

MRK

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 4, 2025, 7:30 AM EST - 20 hours ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Dec 1, 2025, 8:30 AM EST - 3 days ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Pliant Therapeutics Provides Update on BEACON-IPF

Jun 27, 2025, 4:05 PM EDT - 5 months ago

Pliant Therapeutics Provides Update on BEACON-IPF

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025, 4:03 PM EDT - 7 months ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:05 PM EDT - 7 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 1, 2025, 4:05 PM EDT - 7 months ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 7, 2025, 4:05 PM EDT - 8 months ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Pliant Therapeutics: An Activist On Deck

Apr 3, 2025, 12:22 PM EDT - 8 months ago

Pliant Therapeutics: An Activist On Deck

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 17, 2025, 8:00 AM EDT - 9 months ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 11:04 AM EDT - 9 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 13, 2025, 7:20 AM EDT - 9 months ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 4:05 PM EST - 9 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 1:32 PM EST - 9 months ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 3, 2025, 9:27 AM EST - 9 months ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Mar 2, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 26, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 25, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 24, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 10 months ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 21, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 3:39 PM EST - 10 months ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 20, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Feb 19, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

Feb 18, 2025, 10:00 AM EST - 10 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

elmono
elmono Dec. 5 at 8:17 AM
$PLRX when does this bio zombie receive a 3 usd cash offering from Tang to take it out of its misery? Over 4 USD in cash per share so shouldn’t take long
0 · Reply
Iightning
Iightning Dec. 5 at 6:47 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PLRX Contract: Dec 19 $1C Entry: 0.30 Exit: 0.55 Return: +83.89% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
Iightning
Iightning Dec. 5 at 12:36 AM
1ightning® Premium Options Alert (Actionable) Ticker: $PLRX Contract: Dec 19 $1C Entry: 0.30 Exit: 0.55 Return: +83.89% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 4 at 9:59 PM
$GRI no matter the bear thesis IM STILL GAMBLING ON iPf DATA. I know what the market prices it at. Look at $PLRX $TVRD $ARCT
2 · Reply
anarquia99
anarquia99 Dec. 4 at 8:58 PM
$PLRX nice rebound I out here
0 · Reply
NolAsrtormZ
NolAsrtormZ Dec. 4 at 8:21 PM
$GRI iPf Data worth at Least 300 million market cap Ask $PLRX lost 900 million market cap $TVRD lost over 300 million market cap $ARCT with a 6 person trial Lost 300 million market cap $GRI bio market cap 6.4 million market U do the math on a 300 million market cap boost
1 · Reply
aw20
aw20 Dec. 4 at 8:15 PM
$PLRX and loaded more at 1.17 👀
0 · Reply
Bellbent
Bellbent Dec. 4 at 8:02 PM
$PLRX they want this under a dollar
0 · Reply
cristiraj
cristiraj Dec. 4 at 8:01 PM
$PLRX merck want to buy them very cheap
0 · Reply
sandman7473
sandman7473 Dec. 4 at 7:59 PM
$PLRX loading walls are up. think there are dumping to load. Data was good.
0 · Reply
GTMStox
GTMStox Dec. 4 at 7:53 PM
$PLRX Wow, with the price action, their drug must have caused more cancer. I guess this movement is justified. The market is always so right and honest.
0 · Reply
Bazzzigar
Bazzzigar Dec. 4 at 7:32 PM
$PLRX join with HIMS
0 · Reply
anarquia99
anarquia99 Dec. 4 at 7:20 PM
$PLRX 10 cents more down and it’s almost close to touch the 52 weeks low
0 · Reply
Jobuh
Jobuh Dec. 4 at 7:15 PM
$PLRX
0 · Reply
anarquia99
anarquia99 Dec. 4 at 7:15 PM
$PLRX 1.21 buying more for the rebound
0 · Reply
YungnredE
YungnredE Dec. 4 at 7:11 PM
$PLRX were the results fatal? Ouch
0 · Reply
MrTicker
MrTicker Dec. 4 at 6:56 PM
$PLRX Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors BENZINGA 12:53 PM ET 12/4/2025 Pliant Therapeutics, Inc (PLRX) . is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.
0 · Reply
GTMStox
GTMStox Dec. 4 at 6:52 PM
$PLRX I guess the results had to be treacherous for this type of price action
0 · Reply
heroengine
heroengine Dec. 4 at 5:19 PM
$PLRX conference call in 10 minutes 🚀
1 · Reply
Ml95
Ml95 Dec. 4 at 4:33 PM
$PLRX what’s the news? and why the sudden drop?
0 · Reply
MadHatterTrades74
MadHatterTrades74 Dec. 4 at 4:16 PM
$PLRX As I read this feed, I see people worrying about what if they’re single remaining asset fails? well, they would do exactly what $ANNX did when they were flushed with cash, they bought a new pipeline asset and then they mooned
3 · Reply
Arcides
Arcides Dec. 4 at 4:11 PM
$PLRX sold the news hard...
0 · Reply